The evolving obesity paradigm story: from heart failure to atrial fibrillation

Stephan von Haehling¹, Wolfram Doehner^{2

3}, Stefan D Anker³

Affiliations

¹ Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany and German Center for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.
² Centre for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Germany.
³ Division of Cardiology and Metabolism at Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany.

Comment

Stephan von Haehling et al. Eur Heart J. 2019.

. 2019 May 14;40(19):1550-1552.

doi: 10.1093/eurheartj/ehz082.

Stephan von Haehling¹, Wolfram Doehner^{2

3}, Stefan D Anker³

¹ Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany and German Center for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.
² Centre for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Germany.
³ Division of Cardiology and Metabolism at Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany.

No abstract available

Comment on

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Boriani G, et al. Eur Heart J. 2019 May 14;40(19):1541-1550. doi: 10.1093/eurheartj/ehy861. Eur Heart J. 2019. PMID: 30624719 Clinical Trial.